Company Profiles

driven by the PitchBook Platform

Axerion Therapeutics

Description

Developer of disease-modifying therapeutics designed to treat spinal cord injury (SCI), stroke recovery and Alzheimer's disease. The company's Nogo Receptor platform and small molecule oral compounds block the binding of β-amyloid (Aβ) oligomers to PrP in the brain, enabling patients with central nervous system disorders to get proper treatment by stimulating regrowth in axons.

2010

Founded

PRIVATE

Status

1-10

Employees

Conv. Debt

Latest Deal Type

$500k

Latest Deal Amount

$1.66M

Total Amount Raised

Description

Developer of disease-modifying therapeutics designed to treat spinal cord injury (SCI), stroke recovery and Alzheimer's disease. The company's Nogo Receptor platform and small molecule oral compounds block the binding of β-amyloid (Aβ) oligomers to PrP in the brain, enabling patients with central nervous system disorders to get proper treatment by stimulating regrowth in axons.

Website:

www.axeriontherapeutics.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Other Pharmaceuticals and Biotechnology

Primary Office

157 Church Street 19th Floor New Haven, CT 06510United States +1 (203) 208-2384
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Axerion Therapeutics's full profile, request a free trial.

Axerion Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Axerion Therapeutics Investors (2)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Connecticut InnovationsVenture CapitalMinority000 0000000 0000
State of ConnecticutGovernment000 0000000 0000
Connecticut Innovations Venture Capital
State of Connecticut Government

Axerion Therapeutics Executive Team (7)

NameTitleBoard
Seat
Contact
Info
George Maynard Ph.DChief Scientific Officer & President
Stanley ChoyActing Chief Financial Officer
Dana Wirak Ph.DDirector
Sylvia McBrinnCo-Founder & Board Member
Amanda Hayward Ph.DCo-Founder
George Maynard Ph.D Chief Scientific Officer & President
Stanley Choy Acting Chief Financial Officer
Dana Wirak Ph.D Director
Sylvia McBrinn Co-Founder & Board Member
Amanda Hayward Ph.D Co-Founder

Axerion Therapeutics Board Members (5)

NameRepresentingRoleSinceContact
Info
David ScheerSelfChairman000 0000
John PuzissSelfBoard Member000 0000
Lillian MuConnecticut InnovationsSenior Investment Associate000 0000
Russell TweeddaleConnecticut InnovationsManaging Director, Investments000 0000
Sylvia McBrinnAxerion TherapeuticsCo-Founder & Board Member000 0000
David Scheer Chairman Self
John Puziss Board Member Self
Lillian Mu Senior Investment Associate Connecticut Innovations
Russell Tweeddale Managing Director, Investments Connecticut Innovations
Sylvia McBrinn Co-Founder & Board Member Axerion Therapeutics
Request full access to PitchBook